Astellas CEO Naoki Okamura is putting a “patient axis” operating model, a broader portfolio of strategic brands and a new generation of science to work in the company’s bid to return to record growth.
News|Podcasts|December 21, 2023
Balancing Costs and Data Integrity: Maximizing ROI with Lab Software Solutions
Author(s)LabVantage Solutions
Explore the implementation of enterprise laboratory software and the start of a digital transformation in your lab with an industry expert who discusses maximizing returns on investment, upholding data integrity while managing cost containment, and adopting digital best practices. This podcast addresses critical topics such as cybersecurity, regulatory compliance and fiscal strategy for pharmaceutical labs and offers valuable insights for professionals at the crossroads of technology, finance, and pharmaceutical regulations. Discover how laboratories can use software solutions to surpass industry standards while managing costs with Bob Voelkner, Vice President, Sales and Marketing, LabVantage Solutions, Inc.
Related to this article
As established gains in personalized and targeted therapy have enabled increasingly precise approaches to disease, novel technologies are expanding what is possible while creating new challenges for drug developers.
TRexBio and Retension Pharmaceuticals priced IPOs, raising a combined $161.7 million to advance their immunology and hypertension pipelines ahead of their Nasdaq debuts.
The FDA approved Tecentriq plus chemotherapy for stage III dMMR colon cancer, Roche’s 12th US indication for the immunotherapy.
Pharma's chain of custody model is migrating into food and consumer goods — and becoming a cross-industry differentiator.
Ultragenyx sells a rare pediatric disease priority review voucher for $210 million, Viatris acquires Pacira BioSciences for $1.65 billion, and Peter Young surveys a steadying biopharma outlook.
Improved financing conditions and accelerating M&A are creating new opportunities, but policy uncertainty, patent expirations and persistent funding pressures continue to shape the outlook for pharma and biotech.
Exploring the emergence of agentic ecosystems in transforming data accessibility and ensuring reliable answers reach the people making decisions while there is still a choice to make.
Trending on PharmExec
1
Viatris Acquires Pacira BioSciences for $1.65 Billion
2
Ultragenyx to Sell Rare Pediatric Disease Priority Review Voucher for $210 Million
3
Roundup: TRexBio & Retension Pharmaceuticals Announce IPO Pricing
4
FDA Approves Tecentriq for Stage III dMMR Colon Cancer
5